23:47 , May 23, 2018 |  BC Innovations  |  Translation in Brief

Toward Tailored Chemo

A group at UCSF is bringing precision medicine to chemotherapies, with a predictive model for drug responses based on single gene deletions. Despite advances in immuno-oncology and targeted therapies, nearly 95% of cancer patients receive chemotherapy...
18:29 , May 15, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers; other

TECHNOLOGY: Gene profiling; computational models A gene profiling-based computational model could identify single-gene deletions as markers of response to therapies for high-grade serous ovarian cancer (HGSOC) patients. The model is generated by transfecting a human breast...
19:50 , Apr 20, 2018 |  BC Week In Review  |  Company News

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
23:47 , Apr 16, 2018 |  BC Extra  |  Tools & Techniques

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
19:54 , Nov 6, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of SMARCA2 RNA could help predict responses to EZH2 inhibitors in cancers harboring mutations in the SWI/SNF complex. In 20 human ovarian, lung, gastrointestinal and other cancer cell lines with mutations...
19:19 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting HDAC6 could help treat ARID1A-mutant clear cell ovarian cancer. In four ARID1A-mutant clear cell ovarian cancer cell lines, the HDAC6 inhibitor rocilinostat or shRNA targeting HDAC6...
19:18 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

CASI reports Phase II data for ENMD-2076 in clear cell ovarian cancer

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, CASI Pharmaceuticals Inc. (NASDAQ:CASI) reported data from 37 evaluable patients with recurrent clear cell ovarian cancer in a Phase II...
08:00 , Nov 10, 2014 |  BioCentury  |  Product Development

Following the Blueprint

After completing an annotated library to bootstrap the development of inhibitors of almost any kinase, Blueprint Medicines has disclosed two test-case inhibitors intended to show how the library can tackle tough targets. The company now...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer AT rich interactive domain 1A (ARID1A); ARID1B; breast cancer 1 early onset (BRCA1); BRCA2; K-Ras (KRAS); phosphoinositide...